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Abstract: Upper abdominal exenteration for upper abdominal malignanc-
ies was carried out in 15 patients with removal ofthe liver, spleen, pancreas, 
duodenum, all or part of the stomach, proximal jejunum and ascending 
and transverse colon. Organ replacement was with the liver, pancreas and 
duodenum plus, in some cases, a short segment of jejunum. Eleven of the 
15 patients survived for more than 4 months; 2 died, after 6t and 10 
months, of recurrent tumor. Of the 9 patients who are surviving after 6t 
to 14 months, recurrent tumor is suspected in only I and proven in none. 
Four patients with sarcomas and carcinoid tumors (2 each) have had no 
recurrences. The other 5 survivors had duct cell cancers (3 examples), a 
cholangiocarcinoma (1 example), and a hepatoma (1 example). The ex-
perience so far supports further cautious trials with this drastic cancer 
operation. 
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Between 22 July 1988 and 24 March 1989, 15 pa-
tients with otherwise untreatable intraabdominal 
malignancies underwent upper abdominal exenter-
ation, followed by transplantation of the liver in 
continuity with the pancreas and duodenum. The 
first 10 of these cases have been reported previously 
(1). The purpose of the present report is to provide 
an accounting of all 15 patients who now have 
potential survival ranging from 6 to 14 months. 
Methods 
Case material 
The patients were 27 to 49 years old. There were 
9 men and 6 women (Table 1). Three of the 15 
patients had liver failure and were originally sent 
to us for consideration of transplantation for that 
reason. Jaundice and weight loss were common. 
The previous operations in these patients are 
summarized in Table 2. A previous hepatic resec-
tion had been carried out in 2 patients. One had 
had a Klatskin tumor with Roux-y biliary recon-
struction 2.5 yr earlier, and the other had had a 
left hepatic trisegmentectomy 8 months previously 
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for treatment of a cholangiocarcinoma. Both of 
these patients with previous resections were physi-
Cians. 
The tumor pathology in the 15 cases is summar-
ized in Table 2. There were 7 duct cell carcinomas, 
2 cholangiocarcinomas of the liver, 2 small bowel 
sarcomas, 3 neuroendocrine tumors, and 1 hepato-
cellular carcinoma. In most cases, there were meta-
stases with as many as 4 organs involved by tumor. 
Particular attention was paid to the lymph nodes 
in the specimen. Five of the 15 patients had positive 
nodes. 
The essence of the operation is shown in Fig. 1. 
The organs removed included the liver, stomach, 
pancreas, spleen, duodenum, proximal jejunum, 
and ascending plus transverse colon. Although the 
operation had several variations (1), the usual reci-
pient procedure and gastrointestinal reconstruction 
is that in Fig. 1. A veno-venous bypass was used 
during the recipient organ removal, permitting by-
pass of systemic venous blood from the vena cava 
and of splanchnic blood from the superior mesen-
teric vein during a 1- to 3-hour interval. In 2 pa-
tients (Cases 6 and 14) retransplantation was 
necessary due to primary non-function of the initial 
organ cluster. 
Postoperatively, the patients received immuno-
suppression with cyclosporine and prednisone to 
which azathioprine was added when and if the 
white blood count was more than 5000 mm3• OKT3 
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Table 1. Recipient patients 
Preop. Liver Function 
Prothrombin Date of 
No. Age Sex Race Bilirubin Albumin Time Operation 
1 27 M W 2.3 3.6 11 .3 7/22/88 
2 31 F W 0.6 3.8 12.9 7/28/88 
3 35 F W 3.2 4.2 13.0 8/26/88 
4 43 M W 0.6 3.6 10.7 9/17/88 
5 37 F W 0.3 3.8 11.9 10/27/88 
6 27 M W 0.3 1.9 13.9 11/23/88 
11 /26/88 
7 29 M W 9.3 2.9 14.0 11/25/88 
8 30 M W 6.0 4.8 15.3 12/1189 
9 47 F W 14.0 3.1 13.2 1/1189 
10 40 F W 8.9 3.6 10.5 1/12/89 
11 49 M W 1.0 3.9 11.8 1/18/89 
12 39 M W 9.3 3.5 15.5 2f7189 
13 49 M W 0.9 4.2 12.2 2/24/89 
14 33 M 0 0.7 4.1 12.4 2/27/89 
3/03/89 
15 41 F W 0.5 2.9 12.0 3/24/89 
Fig. 1. Usual gastrointestina l reconstructions in patients with 
upper abdominal exenteration and organ cluster transplan-
tation. 
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was used with the indication of rejection or with 
the suspicion of graft-versus-host disease. 
Adjuvant cancer therapy was not given . Diet 
was resumed when requested by the patient and 
advanced quickly to multiple small feedings . All 
15 patients were treated during operation and for 
7 to 21 days afterward with the synthetic somato-
statin, sandozstatin®, which has been shown to 
minimize experimentally caused pancreatitis. 
Results 
Mortality 
The causes of death are tabulated in Table 3. In 
the patients who died early (9 to 112 d), there 
was no evidence of tumor detected clinically or at 
autopsy, although Patient 12 had a positive margin 
in the original specimen. In 2 instances, the deaths 
were due to slough or fistula of the pancreas. Pri-
Fig. 2. Gastrointestinal series obtained in Patient 5, showing 
homograft duodenum and jejunum in continuity with patient 's 
own stomach and jejunum. This segment of intestine has func-
tion as a true intestinal homograft for II months. 
. . 
,------------------
Organ cluster procedures 
mary graft non-function in a 3rd could not be of having recurrence. This is a young physician 
rectified with retransplantation. The 4th patient who had a thoracic CT scan 7 months postopera-
died 57 d postoperatively of massive gastrointesti- tively which revealed multiple nodules in the lower 
nal bleeding caused by CMV gastroenteritis. lung fields. These lesions have been stable for 3 
Two late deaths were caused by widespread tu- months. The decision was made not to biopsy the 
mor recurrence after 10 and 6 months. Both pa- lung nodules since it was not thought justified in 
tients (Cases 3 and 9), had metastatic disease pres- any event to use chemotherapy. The patient is 
ent at the time of operation, although this was not stable clinically with completely normal liver and 
realized until the preoperative X-rays were re- pancreas graft function 10 months after resection 
viewed later. for a duct cell carcinoma. 
Two patients with carcinoid tumors and massive 
Surviving patients liver metastases, as well as the 2 with sarcoma in 
multiple organs have no evidence of recurrence. 
Nine of the 15 patients are still living with survival None of the sarcoma patients had lymph node 
of 6 to 14 months (Table 4). Only one is suspected involvement, while in I (Case 5) of the 2 surviving 
Table 2. Characteristics of tumors 
Primary Metastases 
Lymph Previous 
Case Histopathology Location Size Liver Pancreas Bowel Nodes Other Treatment 
duct cell common duct diffuse minor no no 0/9 no none 
carcinoma 
sclerosing 
cholangitis 
2 spindle cell sarcoma duodenum 5 cm extensive no no 0/38 no none 
3 duct cell carcinoma hilum 9.5 cm extensive no no 12/50 lungs* none 
sclerosing cholangitis 
4 spindle cell sarcoma duodenum (4th) 8 COl extensive no no 0/57 no none 
5 carcinoid duodenum (2nd) 1.8 cm extensive no no 5/35 no adriamycin 
and 
tumor 
embolization 
6 carcinoid stomach 3 em extensive no no 2/27 no open liver 
biopsy 
7 recu rrent duct cell intrahepatic 11 cm extensive no extensive 0/28 no resection of 
klatskin tumor 
hepatica-
jejunostomy 
on 3/26/86 
followed by 
4500 RADS 
8 duct cell carcinoma liver hilum 7.5 cm regional no no 0/94 no exploratory 
laparotomy 
9 duct cell carcinoma common duct 10 cm extensive head and no 6/30 portal none 
body vein, skull* 
10 duct cell carcinoma liver hilum 11.5 cm direct 0 0 0170 no percutaneous 
invasion transhepatic 
stent 
11 cholangiocarcinoma liver 14 em extensive head no 0/28 no none 
12 duct cell carcinoma common 6 cm extensive no no 2/21 positive total 
sclerosing cholangitis duct margin at colectomy 
the hepatic and 
vein ileostomy 
13 recurrent liver multiple extensive no no 0/34 no left triseg-
cholangiocarcinoma lesions mentectomy 
up to 5 cm 8 months 
previously 
14 hepatocellular liver 11 cm extensive no no 0/25 portal vein exploratory 
carcinoma, PNCB** invasion laparotomy 
15 carcinoid pancreas 4.5 cm extensive stomach 0/38 no open liver 
colon biopsy 
'* PNCB = Hepatitis B postnecrotic Cirrhosis; * Diagnosed postoperatively upon retrospective review of X-ray films. 
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Table 3. Causes of death 
Case 
Number Primary Diagnosis 
6 
11 
12 
9 
3 
carcinoid 
cholangiocarcinoma 
duct cell carcinoma and sclerosing cholan-
gitis 
duct cell carcinoma and sclerosing cholan-
gitis 
duct cell carcinoma 
duct cell carcinoma and sclerosing cholan-
gitis 
, Cytomegalovirus. 
Cause of Death 
candida sepsis and multiorgan failure after 
retransplantation 
acute myocardial infarction secondary to 
massive 61 bleeding 
sepsis, disseminated CMV* and multiorgan fail-
ure secondary to pancreatic fistula 
bacterial septicemia and multiple organ failure 
secondary to pancreatic fistula 
metastasic disease (lungs, bones and brain) 
metastasic disease (lungs and bones) 
Autopsy Findings 
invasive systemic candidiasis - no evidence 
of residual disease 
acute myocardial infarction, massive 61 bleed-
ing, multiple ulcerations of the gastrointestinal 
tract secondary to disseminated CMV* - no 
evidence of residual disease 
not done 
not done 
not done 
not done 
Survival 
in Days 
9 
57 
72 
112 
197 
304 
patients with a carcinoid there were metastases in 
5 lymph nodes. All of these patients had clean 
resection margins in spite of the fact that the tu-
mors were truly massive. 
seemingly have enjoyed their new weight status, 
having previously been self-classified as obese. 
Patient 5 was of special interest because of the use 
of her entire duodenum and proximal jejunum as a 
segment in continuity of the gastrointestinal tract 
(Fig. 2). This piece of small bowel which has now 
functioned as a true intestinal homograft for 11 
months has continued to be complication-free. This 
patient was explored for a small bowel intestinal ob-
struction 6 months after her transplantation (by Dr. 
Wallis MarshofSt. Louis) and was found to be com-
pletely free of intra abdominal tumor. 
The other 4 patients who are free of malignancy 
had hepatoma (1 example), recurrent cholangiocar-
cinoma after a left trisegmentectomy 9 months pre-
viously (1 example), and duct cell carcinoma (2 
examples). 
Quality of life 
The 9 surviving patients have had a very acceptable 
quality oflife which has improved with the passage 
of time. At first, all of the patients had very severe 
weight loss and it was feared that they might become 
nutritional cripples. However, the weight loss was 
reversed in 2 of the patients and maintained at a 
stable level in 7 others (Table 4). Some of the patients 
The gastrointestinal tract function of the survi-
ving patients is summarized in Table 4. In patients 
with more than 6 months survival, frequent small 
feedings have been reduced (Table 4). The diarrhea 
which was universal early after operation has 
changed to more formed and less frequent bowel 
movements. 
Table 4. Current status of the surviving patients 
Latest Postop. Insulin Early Satiety and/or Number of Meals 
Liver Function or Enzyme Weight Pain with meals per day Stools/day 
Patient Bilirubin Albumin Protime Replacement S; 6 months > 6 months S; 6 months > 6 months S; 6 months > 6 months Follow-
Number (mg%) (mg%) (sec) Preop. Lowest Now Postop. Postop. Postop. Postop. Postop. Postop. up (days) 
2 0.9 4.2 11.2 0 109 95 95 only with no 6 3-5 l' 0-1' 416 
big meals 
4 0.2 3.6 11.3 0 140 112 125 no no 6 3 2* 1-2 364 
5 1.0 4.5 12.4 0 159 137 122 occasionally no 6 3-5 3-4' 1 ' 325 
7 0.5 4.0 12.7 0 141 99 99 no no 6 3-5 2-3* 2-3* 296 
8 0.4 4.1 11.8 0 140 95 124 yes no 6 3 3* 3* 290 
10 0.5 4.0 11.5 0 168 126 126 occasionally no 6 3-4 3* 3* 247 
13 0.6 3.8 12.0 0 121 110 110 no 6 4* 205 
14 0.8 3.1 10.6 0 120 83 86 yes 3 3* 202 
15 0.5 3.9 12.7 0 145 90 98 only with 6 2-3* 177 
big meals 
* Treatment for diarrhea (with dypnoxylate HCL (patients 2, 5, 14, 15) loperomide HCL (patients 7, 10) propantheline bromide (patient 8) and atropine (patient 
13)). 
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Discussion 
The concept upon which this operation was based 
was discussed extensivelv in an earlier publication 
(I). What was done was 'to excise the adult equiva-
lent of most of the embryonal foregut, including 
the stomach, liver, pancreas, duodenum and spleen. 
In addition, the proximal jejunum and the ascend-
ing and transverse colon which derive from the 
upper and lower portions of the midgut were also 
removed. The philosophic question with such an 
operation is whether the mere extension of the 
surgical resection limits would permit extended tu-
mor-free survival of patients whose malignancies 
were so extensive as to preclude conventional 
therapy. 
With each passing month, the answer to this 
question has seemed to be affirmative. Although 
the operation was dangerous, with 4 of the 15 
patients dying within the first 4 postoperative 
months. survival beyond this time has been accept-
able. Only 2 patients have developed recurrences. 
In both patients, the diagnosis was duct cell carci-
nomas with lymph node metastases, and in both 
there was evidence upon retrospective review of the 
X-ray studies that metastases beyond the surgical 
boundaries were already present at the time of 
operation. There has been no recurrence in the 
sarcomas and carcinoid tumors which were excep-
tionally bulky, and there have been examples of 
long tumor-free state in patients with duct cell car-
cinomas, a cholangiocarcinoma, and a hepatoma. 
The evolution in Case 13 was particularly grati-
fying. A surgeon who was the Chairman of a de-
partment in a major European university under-
went a left hepatic trisegmentectomy for a cholan-
giocarcinoma on 5 July 1988. He developed 
recurrences in the residual posterior segment and 
had a cluster operation 8 months later. Since then, 
he has been appointed as Departmental Chairman 
at another University and works full time. 
Thus, there is reason to continue further trials 
of the upper abdominal exentreration procedure, 
Organ cluster procedures 
and to consider cautious exploration of further 
indications for this operation. For example, pa-
tients with carcinomas of the right and transverse 
colon with multiple hepatic metastases might be 
appropriate candidates for the procedure. Acinar 
carinomas of the pancreas with liver metastases 
have not yet been treated. The only discouraging 
observation that can be made from the experience 
so far is the poor survival of patients with bile duct 
cell carcinomas, particularly those with multiple 
lymph node metastases at the time of their oper-
ations. 
Follow-up periods of only 6 to 14 months are 
still inadequate to permit more than tentative con-
clusions, but in this period many of the survivors 
have achieved virtually complete rehabilitation. 
Whether or not the full cluster replacement graft 
is necessary is under study. The upper abdominal 
exenteration has been performed by Tzakis et a!. 
(2) with transplantation of the liver only. The pen-
alty for the more limited procedure is diabetes 
mellitus and exocrine pancreatic insufficiency. 
Eighteen such procedures have been carried out, 
but with follow-ups of a few days to more than 6 
months, it is too early to speculate about which is 
the preferred operation. The cluster replacement 
permits freedom from endocrine and exocrine pan-
creatic insufficiency, and it avoids biliary tract re-
construction. On the negative side, the pancreas 
component of the organ cluster homograft was 
responsible for the death of at least 2 patients. In 
addition, it is much more difficult to find organ 
cluster donors than it is to find donors of livers 
alone. 
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